All In Biotech

NDA 020189 · Mylan Speciality Lp

Felbatol

Felbamate · Oral · Anti-epileptic Agent

NovelPriority reviewOrphan

Last checked: Nov 19, 2026Latest source record: Aug 31, 2012 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1993

Jul 29, 1993

Approved uses

1

Original approval plus efficacy supplements

Registered trials

3

0 Phase 3, 0 recruiting

FAERS reports

1,779

1,266 serious, 89 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING 1. APLASTIC ANEMIA THE USE OF FELBATOL ® (felbamate) IS ASSOCIATED WITH A MARKED INCREASE IN THE INCIDENCE OF APLASTIC ANEMIA. ACCORDINGLY, FELBATOL ® SHOULD ONLY BE USED IN PATIENTS WHOSE EPILEPSY IS SO SEVERE THAT THE RISK OF APLASTIC ANEMIA IS DEEMED ACCEPTABLE IN LIGHT OF THE BENEFITS CONFERRED BY ITS USE (SEE INDICATIONS ). ORDINARILY, A PATIENT SHOULD NOT BE PLACED ON AND/OR CONTINUED ON FELBATOL ® WITHOUT CONSIDERATION OF APPROPRIATE EXPERT HEMATOLOGIC CONSULTATION. AMONG FELBATOL ® TREATED PATIENTS, APLASTIC ANEMIA (PANCYTOPENIA IN THE PRESENCE OF A BONE MARROW LARGELY DEPLETED OF HEMATOPOIETIC PRECURSORS) OCCURS AT AN INCIDENCE THAT MAY BE MORE THAN A 100 FOLD GREATER THAN THAT SEEN IN THE UNTREATED POPULATION (I.E., 2 TO 5 PER MILLION PERSONS PER YEAR). THE RISK OF DEATH IN PATIENTS WITH APLASTIC ANEMIA GENERALLY VARIES AS A FUNCTION OF ITS SEVERITY AND ETIOLOGY;...

What it is approved for

From the label in effect Aug 15, 2025.

INDICATIONS AND USAGE Felbatol ® is not indicated as a first line antiepileptic treatment (see Warnings ). Felbatol ® is recommended for use only in those patients who respond inadequately to alternative treatments and whose epilepsy is so severe that a substantial risk of aplastic anemia and/or liver failure is deemed acceptable in light of the benefits conferred by its use. If these criteria are met and the patient has been fully advised of the risk and has provided written acknowledgment, Felbatol ® can be considered for either monotherapy or adjunctive therapy in the treatment of partial seizures, with and without generalization, in adults with epilepsy and as adjunctive therapy in the treatment of partial and generalized seizures associated with Lennox-Gastaut syndrome in children.

Mechanism: Mechanism of Action The mechanism by which felbamate exerts its anticonvulsant activity is unknown, but in animal test systems designed to detect anticonvulsant activity, felbamate has properties in common with other marketed anticonvulsants. Felbamate is effective in mice and rats in the maximal electroshock test, the subcutaneous pentylenetetrazol seizure test, and the subcutaneous picrotoxin seizure test. Felbamate also exhibits anticonvulsant activity against seizures induced by intracerebroventricular administration of glutamate in rats and N-methyl-D,L-aspartic acid in mice. Protection...

Therapeutic areas: Neurology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • FELBATOL · FELBAMATE 600MG/5ML · SUSPENSION, ORAL · Discontinued · TE AB
  • FELBATOL · FELBAMATE 400MG · TABLET, ORAL · Prescription · TE AB
  • FELBATOL · FELBAMATE 600MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Felbamate" as an intervention, any sponsor and status, largest first.

All 3 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • seizure364
  • drug ineffective263
  • off label use134
  • convulsion124
  • somnolence114
  • condition aggravated92
  • fatigue87
  • drug interaction73
  • vomiting72
  • toxicity to various agents71
  • generalised tonic-clonic seizure68
  • diarrhoea61

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200410
20057
200623
200718
200811
200915
201030
201138
201273
201377
201498
2015128
2016113
201791
2018104
2019128
2020155
2021163
2022119
202383
2024111
2025128
202656

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Felbatol (Felbamate)

2024 spending

$5.7M

Beneficiaries

237

1,837 claims

Per beneficiary

$23,913

$15.52 per unit

View as table
YearSpending
2020$10,001,936
2021$10,012,244
2022$9,457,663
2023$7,319,135
2024$5,667,454

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 66 on PubMed

Sponsor: Mylan Speciality Lp

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.